Zeno Bisoffi
University of Verona
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Zeno Bisoffi.
PLOS Medicine | 2009
Zeno Bisoffi; Federico Gobbi; Andrea Angheben; Jef Van den Ende
Zeno Bisoffi and colleagues discuss a new clinical trial in Zanzibar comparing symptom-based clinical diagnosis of malaria versus clinical diagnosis plus rapid diagnostic tests.
Clinical Infectious Diseases | 2002
Tomas Jelinek; C. Schulte; Ron H. Behrens; Martin P. Grobusch; J. P. Coulaud; Zeno Bisoffi; Alberto Matteelli; J. Clerinx; M. Corachán; Sabino Puente; Ida E. Gjørup; G. Harms; Herwig Kollaritsch; Kotlowski A; A. Björkmann; J. P. Delmont; J. Knobloch; L. N. Nielsen; Juan Cuadros; C. Hatz; J. Beran; Matthias L. Schmid; Marco Schulze; R. Lopez-Velez; K. Fleischer; A. Kapaun; Paul McWhinney; Peter Kern; J. Atougia; G. Fry
Malaria continues to have a high morbidity rate associated among European travelers. Thorough recording of epidemiological and clinical aspects of imported malaria has been helpful in the detection of new outbreaks and areas of developing drug resistance. Sentinel surveillance of data collected prospectively since 1999 has begun within TropNetEurop, a European network focusing on imported infectious diseases. TropNetEurop appears to cover approximately 10% of all patients with malaria seen in Europe. Reports of 1659 immigrants and European patients with Plasmodium falciparum malaria were analyzed for epidemiological information and data on clinical features. Regional data were quite diverse, reflecting local patterns of immigration and international travel. By far, the most infections were imported from West Africa. Europeans had more clinical complications; consequently, all deaths occurred in this group. Compared with European standards, the mortality rate was low (0.6% in Europeans). Data from TropNetEurop member sites can contribute to our understanding of the epidemiological and clinical findings regarding imported falciparum malaria.
Clinical Infectious Diseases | 2002
Tomas Jelinek; Nikolai Mühlberger; G. Harms; M. Corachán; Martin P. Grobusch; J. Knobloch; U. Bronner; Hermann Laferl; A. Kapaun; Zeno Bisoffi; J. Clerinx; Sabino Puente; G. Fry; Marco Schulze; Urban Hellgren; Ida E. Gjørup; Pavel Chalupa; C. Hatz; Alberto Matteelli; Matthias L. Schmid; L. N. Nielsen; S. da Cunha; J. Atouguia; B. Myrvang; K. Fleischer
Travelers have the potential both to acquire and to spread dengue virus infection. The incidence of dengue fever (DF) among European travelers certainly is underestimated, because few centers use standardized diagnostic procedures for febrile patients. In addition, DF is currently not reported in most European public health systems. Surveillance has commenced within the framework of a European Network on Imported Infectious Disease Surveillance (TropNetEurop) to gain information on the quantity and severity of cases of dengue imported into Europe. Descriptions of 294 patients with DF were analyzed for epidemiological information and clinical features. By far the most infections were imported from Asia, which suggests a high risk of DF for travelers to that region. Dengue hemorrhagic fever occurred in 7 patients (2.4%) all of whom recovered. Data reported by member sites of the TropNetEurop can contribute to understanding the epidemiology and clinical characteristics of imported DF.
PLOS Neglected Tropical Diseases | 2013
Ana Requena-Méndez; Peter L. Chiodini; Zeno Bisoffi; Dora Buonfrate; Eduardo Gotuzzo; José Muñoz
Background Strongyloidiasis is frequently under diagnosed since many infections remain asymptomatic and conventional diagnostic tests based on parasitological examination are not sufficiently sensitive. Serology is useful but is still only available in reference laboratories. The need for improved diagnostic tests in terms of sensitivity and specificity is clear, particularly in immunocompromised patients or candidates to immunosuppressive treatments. This review aims to evaluate both conventional and novel techniques for the diagnosis of strongyloidiasis as well as available cure markers for this parasitic infection. Methodology/Principal Findings The search strategy was based on the data-base sources MEDLINE, Cochrane Library Register for systematic review, EmBase, Global Health and LILACS and was limited in the search string to articles published from 1960 to August 2012 and to English, Spanish, French, Portuguese and German languages. Case reports, case series and animal studies were excluded. 2003 potentially relevant citations were selected for retrieval, of which 1649 were selected for review of the abstract. 143 were eligible for final inclusion. Conclusions Sensitivity of microscopic-based techniques is not good enough, particularly in chronic infections. Furthermore, techniques such as Baermann or agar plate culture are cumbersome and time-consuming and several specimens should be collected on different days to improve the detection rate. Serology is a useful tool but it might overestimate the prevalence of disease due to cross-reactivity with other nematode infections and its difficulty distinguishing recent from past (and cured) infections. To evaluate treatment efficacy is still a major concern because direct parasitological methods might overestimate it and the serology has not yet been well evaluated; even if there is a decline in antibody titres after treatment, it is slow and it needs to be done at 6 to 12 months after treatment which can cause a substantial loss to follow-up in a clinical trial.
BMC Infectious Diseases | 2013
Dora Buonfrate; Ana Requena-Méndez; Andrea Angheben; José Muñoz; Federico Gobbi; Jef Van den Ende; Zeno Bisoffi
BackgroundStrongyloidiasis is commonly a clinically unapparent, chronic infection, but immuno suppressed subjects can develop fatal disease. We carried out a review of literature on hyperinfection syndrome (HS) and disseminated strongyloidiasis (DS), in order to describe the most challenging aspects of severe strongyloidiasis.MethodsWe conducted a structured search using PubMed to collect case reports and short case series on HS/DS published from 1991 to 2011. We restricted search to papers in English, Spanish, Italian and French. Case reports were classified as HS/DS according to given definitions.ResultsRecords screened were 821, and 311 were excluded through titles and abstract evaluation. Of 510 full-text articles assessed for eligibility, 213 were included in qualitative analysis. As some of them were short case series, eventually the number of cases analyzed was 244.Steroids represented the main trigger predisposing to HS and DS (67% cases): they were mostly administered to treat underlying conditions (e.g. lymphomas, rheumatic diseases). However, sometimes steroids were empirically prescribed to treat signs and symptoms caused by unsuspected/unrecognized strongyloidiasis. Diagnosis was obtained by microscopy examination in 100% cases, while serology was done in a few cases (6.5%). Only in 3/29 cases of solid organ/bone marrow transplantation there is mention of pre-transplant serological screening. Therapeutic regimens were different in terms of drugs selection and combination, administration route and duration. Similar fatality rate was observed between patients with DS (68.5%) and HS (60%).ConclusionsProper screening (which must include serology) is mandatory in high - risk patients, for instance candidates to immunosuppressive medications, currently or previously living in endemic countries. In some cases, presumptive treatment might be justified. Ivermectin is the gold standard for treatment, although the optimal dosage is not clearly defined in case of HS/DS.
Tropical Medicine & International Health | 2009
Zeno Bisoffi; Bienvenu Sodiomon Sirima; Andrea Angheben; Claudia Lodesani; Federico Gobbi; Halidou Tinto; Jef Van den Ende
Objectives To assess if the clinical outcome of patients treated after performing a Rapid Diagnostic Test for malaria (RDT) is at least equivalent to that of controls (treated presumptively without test) and to determine the impact of the introduction of a malaria RDT on clinical decisions.
PLOS Neglected Tropical Diseases | 2014
Zeno Bisoffi; Dora Buonfrate; Marco Sequi; Rojelio Mejia; Rubén O. Cimino; Alejandro J. Krolewiecki; Marco Albonico; Maria Gobbo; Stefania Bonafini; Andrea Angheben; Ana Requena-Méndez; José Muñoz; Thomas B. Nutman
Background The diagnosis of Strongyloides stercoralis (S. stercoralis) infection is hampered by the suboptimal sensitivity of fecal-based tests. Serological methods are believed to be more sensitive, although assessing their accuracy is difficult because of the lack of sensitivity of a fecal-based reference (“gold”) standard. Methods The sensitivity and specificity of 5 serologic tests for S. stercoralis (in-house IFAT, NIE-ELISA and NIE-LIPS and the commercially available Bordier-ELISA and IVD-ELISA) were assessed on 399 cryopreserved serum samples. Accuracy was measured using fecal results as the primary reference standard, but also using a composite reference standard (based on a combination of tests). Results According to the latter standard, the most sensitive test was IFAT, with 94.6% sensitivity (91.2–96.9), followed by IVD-ELISA (92.3%, 87.7–96.9). The most specific test was NIE-LIPS, with specificity 99.6% (98.9–100), followed by IVD-ELISA (97.4%, 95.5–99.3). NIE-LIPS did not cross-react with any of the specimens from subjects with other parasitic infections. NIE-LIPS and the two commercial ELISAs approach 100% specificity at a cut off level that maintains ≥70% sensitivity. Conclusions NIE-LIPS is the most accurate serologic test for the diagnosis of S. stercoralis infection. IFAT and each of the ELISA tests are sufficiently accurate, above a given cut off, for diagnosis, prevalence studies and inclusion in clinical trials.
PLOS Neglected Tropical Diseases | 2013
Zeno Bisoffi; Dora Buonfrate; Antonio Montresor; Ana Requena-Méndez; José Muñoz; Alejandro J. Krolewiecki; Eduardo Gotuzzo; Maria Alejandra Mena; Peter L. Chiodini; Mariella Anselmi; Juan Moreira; Marco Albonico
Strongyloidiasis remains an underestimated public health problem, just as it was at the dawn of last century.
Malaria Journal | 2004
Nikolai Mühlberger; Tomas Jelinek; Joaquim Gascón; M Probst; T Zoller; Mirjam Schunk; Jiri Beran; Ida E. Gjørup; Ron H. Behrens; Joannes Clerinx; Anders Björkman; Paul McWhinney; Alberto Matteelli; Rogelio López-Vélez; Zeno Bisoffi; Urban Hellgren; Sabino Puente; Matthias L. Schmid; Bjørn Myrvang; Ml Holthoff-Stich; Hermann Laferl; C. Hatz; Herwig Kollaritsch; A. Kapaun; J. Knobloch; J Iversen; Kotlowski A; Djm Malvy; Peter Kern; G. Fry
BackgroundPlasmodium vivax is the second most common species among malaria patients diagnosed in Europe, but epidemiological and clinical data on imported P. vivax malaria are limited. The TropNetEurop surveillance network has monitored the importation of vivax malaria into Europe since 1999.ObjectivesTo present epidemiological and clinical data on imported P. vivax malaria collected at European level.Material and methodsData of primary cases of P. vivax malaria reported between January 1999 and September 2003 were analysed, focusing on disease frequency, patient characteristics, place of infection, course of disease, treatment and differences between network-member countries.ResultsWithin the surveillance period 4,801 cases of imported malaria were reported. 618 (12.9%) were attributed to P. vivax. European travellers and immigrants were the largest patient groups, but their proportion varied among the reporting countries. The main regions of infection in descending order were the Indian subcontinent, Indonesia, South America and Western and Eastern Africa, as a group accounting for more than 60% of the cases. Regular use of malaria chemoprophylaxis was reported by 118 patients. With 86 (inter-quartile range 41–158) versus 31 days (inter-quartile range 4–133) the median symptom onset was significantly delayed in patients with chemoprophylaxis (p < 0.0001). Common complaints were fever, headache, fatigue, and musculo-skeletal symptoms. All patients survived and severe clinical complications were rare. Hospitalization was provided for 60% and primaquine treatment administered to 83.8% of the patients, but frequencies varied strongly among reporting countries.ConclusionsTropNetEurop data can contribute to the harmonization of European treatment policies.
Clinical Infectious Diseases | 2003
Nikolai Mühlberger; Tomas Jelinek; Ron H. Behrens; Ida E. Gjørup; J. P. Coulaud; Joannes Clerinx; Sabino Puente; Burchard G; Joaquim Gascón; Martin P. Grobusch; Weitzel T; Thomas Zoller; Herwig Kollaritsch; Jiri Beran; J Iversen; C. Hatz; Matthias L. Schmid; Anders Björkman; K. Fleischer; Zeno Bisoffi; Guggemos W; Knobloch J; Alberto Matteelli; Marco Schulze; Hermann Laferl; Annette Kapaun; Paul McWhinney; Rogelio López-Vélez; Fätkenheuer G; Peter Kern
Previous studies have indicated that age is a risk factor for severe falciparum malaria in nonimmune patients. The objectives of this study were to reevaluate previous findings with a larger sample and to find out how strongly clinical outcomes for elderly patients differ from those for younger patients. Results of adjusted analyses indicated that the risks of death due to falciparum malaria, of experiencing cerebral or severe disease in general, and of hospitalization increased significantly with each decade of life. The case-fatality rate was almost 6 times greater among elderly patients than among younger patients, and cerebral complications occurred 3 times more often among elderly patients. Antimalarial chemoprophylaxis was significantly associated with a lower case-fatality rate and a lower frequency of cerebral complications. Women were more susceptible to cerebral complications than were men. Our study provides evidence that falciparum malaria is more serious in older patients and demonstrates that clinical surveillance networks are capable of providing quality data for investigation of rare events or diseases.